ArticleFolia microbiologica2026
Laser-ablated gold nanoparticles: a novel approach to antimicrobial artificial eyes.
Article in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with artificial eyes often suffer from severe, persistent microbial infections, particularly due to antibiotic-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA). Nowadays, gold nanoparticles (AuNPs) exhibit strong antimicrobial properties, offering a promising solution to this challenge. In this study, laser ablation was employed to create AuNPs, which were added into artificial eye materials during fabrication. The antimicrobial efficacy of laser-ablated AuNPs against resistant bacteria was systematically evaluated using multiple microbiological assays. A colony forming unit and growth kinetic analysis were determined using an ANOVA test. Moreover, Logistic and Gompertz models were performed to visualize the MRSA growth kinetic rate. Our findings show that AuNPs significantly reduce bacterial growth, suggesting their potential as an effective antimicrobial component in ocular prostheses. Theoretically, the Gompertz model was the best-fit model for experimental kinetic data. We have produced a foundational framework for integrating AuNPs into artificial eyes to combat infections, paving the way for the development of novel antimicrobial ocular prostheses.
Indexed as
Identifiers
42091838What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.